Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Thoracic 2CNS 2Sarcoma 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Fallopian Tube Mucinous Adenocarcinoma 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 134pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Letrozole 28Drug Therapy 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23durvalumab 22Albumin-Bound Paclitaxel 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20Specimen Handling 20Filgrastim 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Contrast Media × Gynecologic × Clear all
NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡